We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+7.83%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$658M
AUM Growth
-$44.8M
Cap. Flow
-$69.2M
Cap. Flow %
-10.5%
Top 10 Hldgs %
35.22%
Holding
143
New
39
Increased
27
Reduced
22
Closed
45

Top Buys

Rank Stock Value
1
SNN icon
Smith & Nephew
SNN
+$10.3M
2
STAA icon
STAAR Surgical
STAA
+$7.04M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$6.66M
4
ZBH icon
Zimmer Biomet
ZBH
+$6.03M
5
AVTR icon
Avantor
AVTR
+$4.45M

Top Sells

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$10.4M
2
AXGN icon
Axogen
AXGN
+$6.9M
3
CELG
Celgene Corp
CELG
+$4.72M
4
AXSM icon
Axsome Therapeutics
AXSM
+$4.13M
5
GMED icon
Globus Medical
GMED
+$3.47M

Sector Composition

Rank Sector Weight
1 Healthcare 44.69%
2 Industrials 1.24%
3 Consumer Staples 0.68%
4 Materials 0.13%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXGN icon
101
CALL
Axogen
AXGN
$2.59B
– –
-300,000
Closed -$6.32M
AXGN icon
102
Axogen
AXGN
$2.59B
– –
-322,500
Closed -$6.9M
AXSM icon
103
CALL
Axsome Therapeutics
AXSM
$11.4B
– –
-157,400
Closed -$2.24M
BMY icon
104
CALL
Bristol-Myers Squibb
BMY
$132B
– –
-100,000
Closed -$4.77M
CPRX
105
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-197,594
Closed -$1.01M
DVA icon
106
PUT
DaVita
DVA
$11.7B
– –
-100,000
Closed -$5.43M
DXCM icon
107
CALL
DexCom
DXCM
$33.1B
– –
-60,000
Closed -$1.79M
EHC icon
108
PUT
Encompass Health
EHC
$12.4B
– –
-70,643
Closed -$3.28M
EHTH icon
109
eHealth
EHTH
$40.4M
– –
-30,000
Closed -$1.87M
EW icon
110
PUT
Edwards Lifesciences
EW
$53B
– –
-150,000
Closed -$9.57M
EXAS
111
PUT
DELISTED
Exact Sciences
EXAS
– –
-65,000
Closed -$5.63M
GMED icon
112
Globus Medical
GMED
$11.6B
– –
-80,000
Closed -$3.47M
IONS icon
113
PUT
Ionis Pharmaceuticals
IONS
$9.46B
– –
-50,000
Closed -$4.06M
KPTI icon
114
Karyopharm Therapeutics
KPTI
$44.4M
– –
-6,667
Closed -$584K
MGNX icon
115
CALL
MacroGenics
MGNX
$259M
– –
-13,500
Closed -$243K
MRSN
116
DELISTED
Mersana Therapeutics
MRSN
– –
-7,877
Closed -$1.04M
MYGN icon
117
PUT
Myriad Genetics
MYGN
$311M
– –
-300,000
Closed -$9.96M
PBYI icon
118
CALL
Puma Biotechnology
PBYI
$449M
– –
-18,500
Closed -$718K
PTCT icon
119
PTC Therapeutics
PTCT
$6.23B
– –
-84,338
Closed -$3.17M
QGEN icon
120
CALL
Qiagen
QGEN
$9.05B
– –
-188,611
Closed -$8.14M
QURE icon
121
uniQure
QURE
$3.2B
– –
-7,370
Closed -$440K
SAGE
122
DELISTED
Sage Therapeutics
SAGE
– –
-10,000
Closed -$1.59M
TDOC icon
123
Teladoc Health
TDOC
$1.29B
– –
-57,500
Closed -$3.2M
XBI icon
124
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-50,000
Closed -$4.53M
XLV icon
125
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$44B
– –
-150,000
Closed -$13.8M
2 3 4
5
6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q2 2019 Portfolio in Review

As of Q2 2019, Pura Vida Investments held 143 positions worth $658M, down 6.4% from $703M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Pura Vida Investments withdrew a net $69.2M in Q2 2019, closing 45 positions and reducing 22 holdings. Its most notable exit was Dentsply Sirona, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 36% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Smith & Nephew worth $10.9M.

  • Pura Vida Investments's largest Q2 2019 buy was Smith & Nephew: 250,000 shares worth $10.9M.
  • Pura Vida Investments added most to STAAR Surgical in Q2 2019, an estimated $7.04M increase.
  • Pura Vida Investments's biggest Q2 2019 reduction was Axsome Therapeutics, cutting an estimated $4.13M.
  • Pura Vida Investments fully exited Dentsply Sirona in Q2 2019, selling an estimated $10.4M.
  • Pura Vida Investments's ten largest holdings make up 35% of its $658M portfolio in Q2 2019.
  • Pura Vida Investments opened 39 new positions and closed 45 in Q2 2019.
  • Pura Vida Investments's portfolio value fell 6.4% quarter-over-quarter to $658M.

Based on Pura Vida Investments's 13F filing for Q2 2019, filed 14 Aug 2019.